Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Psychosocial Treatment of Depression in Parkinson's Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2012 by Massachusetts General Hospital.
Recruitment status was:  Active, not recruiting
Brigham and Women's Hospital
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Amy Farabaugh, PhD, Massachusetts General Hospital Identifier:
First received: February 27, 2009
Last updated: November 15, 2012
Last verified: November 2012
The purpose of the study is to examine the effects of a form of talk therapy called cognitive behavior therapy (CBT) in the treatment of major depression in individuals with Parkinson's disease (PD).

Condition Intervention
Major Depressive Disorder
Parkinson's Disease
Behavioral: Cognitive Behavioral Therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Psychosocial Treatment of Depression in Parkinson's Disease

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Response according to the Hamilton Rating Scale for Depression, 17 items (HAM-D 17). [ Time Frame: screen, week 4, week 8, week 12; if applicable, week 16, week 20, week 24 ]

Estimated Enrollment: 80
Study Start Date: April 2007
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Patients randomized to the immediate arm will be given 12 weeks of CBT starting one week after randomization
Behavioral: Cognitive Behavioral Therapy
12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
Other Names:
  • CBT
  • Cognitive Therapy
  • Therapy
  • Psychosocial Intervention
Active Comparator: 2
Patients in the delayed arm will receive 12 weeks of CBT, starting 12 weeks after randomization.
Behavioral: Cognitive Behavioral Therapy
12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
Other Names:
  • CBT
  • Cognitive Therapy
  • Therapy
  • Psychosocial Intervention

Detailed Description:
CBT is a specific type of treatment that has been shown to be as helpful in treating depression as medications for depression. CBT focuses on thoughts, feelings, and behaviors. It focuses on the here and now, rather than the past. CBT offers concrete strategies and skills for coping with depression, PD, and other life problems. Previous research leads us to believe that this type of therapy may help people with PD cope with their depression.

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

In addition to the DSM-IV diagnostic criteria for major depressive disorder, the following conditions must be met for patient eligibility:

  • Written informed consent.
  • Subjects with a primary diagnosis of PD who also currently meet DSM-IV criteria for MDD
  • Subjects must be stable on their anti-Parkinson treatment, as defined by no medication changes over the past 6 weeks
  • Subjects may be taking an antidepressant as long as they have had a stable dose for up to 6 weeks and do not alter the dosage during the course of the study
  • Men or women 40-80 years of age
  • HAMD-17 scores > 14 at screen visit
  • Score of 25 or greater on the Mini-Mental Status Examination
  • Willing to come to MGH for screening and study participation

Exclusion Criteria:

Patients meeting any of the following criteria are to be excluded from the study:

  • Subjects who, in the investigator's judgment, pose a current, serious suicidal or homicidal risk
  • Patients who would not be appropriate for a delayed CBT control due to the severity of their depression based on clinical judgment as well as HAMD-17 scores > 28
  • The following DSM-IV diagnoses: 1) substance use disorders, including alcohol dependence, active within the last 3 months; 2) schizophrenia; 3) delusional disorder; 4) psychotic disorders not elsewhere classified; 5) bipolar disorder; 6) MDD with psychotic features
  • Subjects who meet DSM-IV criteria for dementia
  • Severe, unstable concurrent medical conditions (determined by his/her physician) that are likely to require hospitalization within six months from study entry (e.g., a patient with severe congestive heart failure who has a history of recent hospital admissions)
  • Subjects may not be receiving a psychosocial intervention that is specific for depression; psychosocial interventions not specific for depression (e.g., couples counseling) and established for three or more months before screen visit are allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00853346

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Amy Farabaugh, PhD
Brigham and Women's Hospital
Beth Israel Deaconess Medical Center
Principal Investigator: Amy Farabaugh, PhD Massachusetts General Hospital
  More Information

Responsible Party: Amy Farabaugh, PhD, Director, Psychotherapy Research, Depression Clinical & Research Program, Massachusetts General Hospital Identifier: NCT00853346     History of Changes
Other Study ID Numbers: MH076037-01
Study First Received: February 27, 2009
Last Updated: November 15, 2012

Keywords provided by Massachusetts General Hospital:
Parkinson's Disease
Major Depression
Cognitive Behavioral Therapy

Additional relevant MeSH terms:
Depressive Disorder
Parkinson Disease
Depressive Disorder, Major
Behavioral Symptoms
Mood Disorders
Mental Disorders
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases processed this record on April 21, 2017